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Abstract
Background: MicroRNAs (miRNAs) are a class of small non-coding RNAs, which post-transcriptionally repress the
expression of genes involved in cancer initiation and progression. Although some miRNAs that target many signaling
pathways (also called universe miRNAs) are supposed to play a global role in diverse human tumors, their regulatory
functions in gynecological cancers remain largely unknown. We investigated the biological role and underlying
mechanism of miR-548c (one universe miRNA) in endometrial and ovarian cancer.
Methods: The effects of miR-548c overexpression on cell proliferation, migration and invasion were studied in
endometrial and ovarian cancer cells. TWIST1 (Twist) was identified as a direct miR-548c target by western blot analysis
and luciferase activity assay. The expression of miR-548c and Twist were examined by qRT-PCR in endometrial and
ovarian cancer tissues.
Results: Here, we report that miR-548c is down-regulated in endometrial and ovarian cancer tissues when compared
to normal tissues, and our meta-analysis reveal that decreased miR-548c expression correlates with poor prognosis in
endometrial cancer patients. We show that in endometrial and ovarian cancer cells, ectopic expression of miR-548c
significantly inhibits whereas knockdown of miR-548c dramatically induces cancer cell proliferation, migration and
invasion. By using luciferase reporter assay, we demonstrate that Twist, a known oncogene in endometrial and ovarian
cancers, is a direct target of miR-548c. Furthermore, the expression of Twist partially abrogates the tumor suppressive
effects of miR-548c on cell migration and invasion.
Conclusion: These findings suggest that miR-548c directly downregulates Twist, and provide a novel mechanism for
Twist upregulation in both endometrial and ovarian cancers. The use of miR-548c may hold therapeutic potential for
the treatment of Twist-overexpressing tumors.
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Background
Metastasis is the main cause of death among patients
with endometrial cancer (EC, the most frequently diag-
nosed gynecologic malignancy) cbl1, 2] and ovarian can-
cer (OC, the most lethal gynecological cancer) [3]. The
initial steps of metastasis include the detachment and
migration of cancer cells and subsequent invasion into
surrounding tissues [4]. Epithelial-to-mesenchymal
transition (EMT) is considered a key step in metastasis
of endometrial and ovarian cancer [1, 5, 6], which en-
hances the migratory and invasive capacity of tumor
cells to facilitate malignant progression. Therefore, un-
derstanding the molecular mechanisms that mediate mi-
gration, invasion and EMT process of EC and OC cells
could identify novel molecular targets for future treat-
ments of these cancers.
Twist1 (Twist) is a critical oncogene that is overex-
pressed and plays important roles in EMT induction in
EC and OC [1, 7, 8]. High Twist expression positively
correlated with deep myometrial invasion and poor
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outcome in EC [9]. Aberrant expression of Twist in OC
correlated with advanced tumor stage and predicted a
poor clinical outcome [10, 11]. MicroRNAs (miRNAs)
are a class of small non-coding RNA molecules that
regulate gene expression via interactions with the 3’-un-
translated regions (UTRs) of mRNAs targets, causing
translational suppression or mRNA decay. MiRNAs con-
trol metastatic progression [12, 13], and act as either
tumor suppressors or oncogenes in EC and OC [1, 14].
Although a number of miRNAs, such as miR-106b and
miR-543, have been reported to suppress the expression
of Twist and EC cell invasion [15, 16], miRNAs affecting
Twist expression in EC and OC is still not completely
understood. Recently, two distinct classes of microRNAs:
universe miRNAs (for example, miR-34a) that regulate
many signaling pathways, as well as intra-pathway miR-
NAs that target multiple genes within a single signaling
pathway, have been identified [17]. Universe microRNAs
are predicted to affect more targets/signaling pathways,
and might play a global role in tumor cells [17]. Of
interest, several universe miRNAs (including miR-548a/
b/c, etc.) belong to the same miR-548 family [17] and
have been implicated in tumorigenesis [18, 19], however
their regulatory functions in gynecological cancers re-
main largely unknown.
In this study, we investigated the biological func-
tions and underlying mechanism of miR-548c in EC
and OC, and provide in vitro evidence that miR-548c
inhibits migration and invasion in both EC and OC
cells by directly targeting Twist. We further demon-
strate that miR-548c expression inversely correlates
with Twist expression in EC and OC tissues and the
downregulation of miR-548c is associated with poor
prognosis in EC patients.
Methods
Cell culture and transient transfection
The human EC cell lines (RL95-2 and HEC-1) and
human OC cell lines (SKOV-3 and OVCAR3) were
obtained from Chinese Academy of Sciences Commit-
tee on Type Culture Collection Cell Bank, Shanghai,
China. These cells were cultured in DMEM/F12
medium (Invitrogen, Shanghai) or PRMI-1640 medium
(Gibco, Carlsbad, CA, USA) supplemented with 10 % fetal
bovine serum (FBS, Invitrogen, Shanghai). MiR-548c
mimic (40 nM), antisense miR-548c inhibitor (40 nM),
Twist siRNA (5 nM) and respective negative controls were
purchased from Ambion (TX, USA), and were transfected
using Lipofectamine 2000 (Invitrogen, CA, USA), accord-
ing to the manufacturer’s instructions. Transient transfec-
tion of Twist cDNA plasmids (OriGene, MD, USA) were
performed with Lipofectamine Plus reagent (Invitrogen,
CA, USA) according to the manufacturer’s protocol.
RNA extraction and real-time qRT-PCR
Total RNA was extracted using TRIzol reagents (Invitro-
gen, CA, USA). The miRNA qRT-PCR was performed
using the NCode miRNA qRT-PCR analysis (Invitrogen,
CA, USA). Forward primers for miRNA detection are
the exact sequence of mature miR-548c-3p. For mRNA
analysis, RT reaction was carried out using 100 ng total
RNA with the PrimeScript RT reagent kit (Takara,
Japan). Real-time qRT-PCR was performed using the
Takara SYBR Premix Ex Taq II (Takara, Japan). Primers
used for the amplification of E-cadherin [20], N-cadherin
[20], CD133 [21], MMP-9 [22] and GAPDH [22] have
been previously described. All miRNA and mRNA quan-
tification data were normalized to GAPDH. Results were
given as the fold change relative to controls.
Cell proliferation assay and apoptosis assay
To evaluate cell proliferation, 5 × 103 cells were plated in
96-well plates for 24 h, and then transfected with
miRNA mimic/inhibitor with or without Twist siRNA or
Twist cDNA vector. At 72 h, cell proliferation was deter-
mined by the Cell Counting Kit-8 (Dojindo, Japan). The
absorbance was determined at 450 nm using a micro-
plate reader, and data were expressed as the percentage
of absorbance relative to controls. For cell apoptosis
assay, cells were transfected for 72 h and apoptotic cells
were identified using the DeadEnd Colorimetric TUNEL
System kit (Promega, WI, USA), following the manufac-
turer’s instructions. Cell apoptosis was quantified as the
numbers of apoptotic cells found in 15 random fields.
The ratio of dead/total cell number was calculated.
Cell migration and invasion assay
Cells were transfected for 24 h and then seeded into
upper chamber of Boyden chambers coated with or
without Matrigel as described previously [23–25]. After
incubation for 24 h, migration and invasion were stained
and counted under a light microscope. Relative migra-
tion and invasion activities were expressed as the fold
change over respective controls.
Western blot
Cells were harvested 48 h after transfections. Whole-cell
protein extracts were prepared using the M-Per Mamma-
lian Protein Extraction Reagent (Pierce Biotechnology,
MA, USA) according to the manufacturer’s instructions.
Total proteins (40 μg) were loaded onto 10 % SDS-PAGE
for immunoblots with antibodies to Twist (Abcam,
ab50887) and GAPDH (Santa Cruz, sc-47724). Primary
antibodies were used at a dilution of 1:1000.
Luciferase activity assay
The Twist 3’-UTR luciferase vectors was obtained from
OriGene (Rockville, MD, USA). A quick-change site-
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directed mutagenesis kit (Stratagene, CA, USA) was
used to mutate the miR-548c-binding site. Luciferase
activity was measured at 24 h after transfection using
the dual-luciferase reporter assay system (Promega, WI,
USA) as previously reported [15].
Benign and tumor tissues
50 pairs of primary EC and adjacent non-tumor endomet-
rial tissues, 60 epithelial OC tissues and 20 normal epithe-
lial ovarian tissues were collected in the China-Japan Union
Hospital of Jilin University, China. This study was approved
by the Ethics Committee of China-Japan Union Hospital of
Jilin University and conducted according to the principles
of the Declaration of Helsinki. The patients signed a written
inform consent for the procedures in the study. Samples
were snap-frozen immediately at –80 °C, and total RNA
was isolated using TRIzol reagents.
Statistical analysis
Results are presented as mean ± s.e.m. from at least
three independent experiments performed in triplicate.
2-tailed Student’s t-test was used for statistical analysis.
P-values < 0.05 were defined as significant.
Results
MiR-548c is downregulated in endometrial and ovarian
cancer tissues and decreased miR-548c levels associates
with worse prognosis in patients with endometrial cancer
To examine the levels of miR-548c in EC tissues, we
measured the endogenous miR-548c expression by real-
time quantitative RT-PCR (qPCR) in 50 EC samples and
their adjacent normal tissues. Intriguingly, miR-548c was
significantly decreased in ECs compared with adjacent
normal tissues (Fig. 1a). We also analyzed miR-548c ex-
pression by qPCR in clinical samples of 60 OC tissues
































































































































































































































































Fig. 1 MiR-548c is downregulated in endometrial and ovarian cancer tissues and decreased miR-548c levels associates with worse prognosis in
patients with endometrial cancer. Box plots showing decreased expression of miR-548c (a, b) and increased Twist (c, d) mRNA expression in 50
ECs and matched adjacent normal tissues (top), and in 60 OCs compared to 20 normal ovarian tissues (bottom), assessed by the quantitative real-
time RT-PCR (qPCR) assays. Of note, downregulation of miR-548c (b) and upregulation of Twist (d) was detected in serous, advanced stage and
grade 3 OC samples. Kaplan-Meier survival curves of EC (e) and OC (g) patients in The Cancer Genome Atlas (TCGA) data set were created using
the SurvMicro database. In ECs, high-risk patients exhibited significantly lower levels of miR-548c compared to the low-risk patients (f). h MiR-548c
expression between high-risk and low-risk OCs (TCGA). **P < 0.01
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Decreased miR-548c expression was detected in OC tis-
sues relative to normal ovarian tissues, and the expres-
sions of miR-548c were significantly lower in serous,
advanced stage and grade 3 tumor samples compared
with non-serous, early stage and grade 1/2 tumor sam-
ples (Fig. 1b), indicating that the deregulation of miR-
548c may play a critical role in EC or OC development.
To investigate whether the downregulation of miR-
548c is related with prognosis of EC or OC patients, we
used the SurvMicro web tool [26] to investigate the rela-
tionship between miR-548c levels and prognosis of can-
cer patients. The analysis of published data on EC and
OC from The Cancer Genome Atlas (TCGA) revealed
that the low expression levels of miR-548c were associ-
ated with very poor overall survival in EC patients com-
pared with those patients whose ECs express a high level
of miR-548c (Fig. 1e and f). Although our meta-analysis
of OCs using TCGA data did not show a clear separ-
ation between high-risk OCs and low-risk OCs based on
miR-548c expression (P = 0.425), OC patients whose tu-
mors display low miR-548c expression tend to have
shorter survival (Fig. 1g and h). Thus, these data uncover
an association between the loss of miR-548c expression
and poor survival of EC patients, and indicate that miR-
548c repression might be important for EC/OC growth
and progression.
MiR-548c inhibits proliferation, migration and invasion of
EC and OC cells
To select appropriate model for functional studies, we
first evaluated miR-548c expression in two EC cell lines
(RL95-2 and HEC-1) and OC cell line SKOV-3 using
qPCRs. We found that invasive HEC-1 and SKOV-3
cells express much lower levels of miR-548c, compared
with less invasive RL95-2 and OVCAR3 cells (Fig. 2a).
The downregulation of miR-548c in cancer tissues and
invasive cancer cells implicated that it might have the
tumor suppressive roles in the tumorigenesis and metasta-
sis of EC and OC. To test this, we transiently transfected
anti-miRNA inhibitor against miR-548c (anti-548c) or
control inhibitor (anti-ctr) into RL95-2 or OVCAR3 cells,
and then validated the depletion of miR-548c expression
by qPCR assays (Fig. 2b). Furthermore, the ectopic overex-
pression of miR-548c in HEC-1 and SKOV-3 cells was
achieved by transient transfection of pre-miR-548c mimic
(pre-548c) (Fig. 2c). Then, cell proliferation was measured
by the Cell Counting Kit-8 assay. The downregulation of
miR-548c in RL95-2 and OVCAR3 cells resulted in
greater proliferation rate, whereas forced miR-548c ex-
pression significantly reduced proliferation of HEC-1 and
SKOV-3 cells compared with the control mimic (pre-ctr)
(Fig. 2d). To determine the effect of miR-548c on cell
apoptosis, we examined apoptosis-associated DNA frag-
mentation by using a colorimetric TUNEL staining assay.
MiR-548c knockdown decreased RL95-2 or OVCAR3 cell
death, however miR-548c overexpression caused apoptotic
cell death of HEC-1 and SKOV-3 cells (Fig. 2e). These re-
sults suggest that miR-548c inhibits EC and OC cell pro-
liferation and triggers cell apoptosis.
To verify whether miR-548c affect the progression and
metastasis of EC and OC, we evaluated the effect of ei-
ther knockdown or overexpression of miR-548c on the
migratory and invasive abilities of these cells. Transwell
migration and invasion assays demonstrated that down-
regulation of miR-548c expression significantly pro-
moted migration and invasion of RL95-2 and OVCAR3
cells (Fig. 2f and g). In contrast, transient overexpression
of miR-548c in HEC-1 and SKOV-3 cells significantly
impaired in vitro cell migration and invasion (Fig. 2f, g
and h). Together, these data support that miR-548c acts
as a tumor suppressors to inhibit tumor growth, migra-
tion and invasion in both EC and OC cells.
Twist is a direct target of MiR-548c in EC and OC cells
To explore gene targets and molecular pathways that
could be mediated by miR-548c, we performed compu-
tational target prediction using TargetScan and con-
ducted in silico enrichment analysis of miR-548c-target
genes in KEGG pathways using miRSystem [27]. Of
note, miR-548c-regulated genes can potentially modulate
numerous well-known pathways associated with tumor
growth and metastasis, including pathways in cancer,
mTOR pathway, adherens junction, cell cycle, acute
myeloid leukemia, pancreatic cancer, notch signaling
pathway and jak-stat signaling pathway (Fig. 3a), indicat-
ing the possibility that miR-548c has broad influence
over diverse oncogenic pathways. These findings are
consistent with our results (Fig. 2), supporting the roles
of miR-548c to suppress multiple malignant phenotypes
of EC and OC cells including proliferation, migration
and invasion.
Table 1 Clinical characteristics of 60 ovarian cancer patients
Features Cases (%)
Age (years)
≤55 32 (53.3 %)
>55 28 (46.7 %)
Clinical stage
I–II 19 (31.7 %)
III–IV 41 (68.3 %)
Pathological grade
1–2 24 (40.0 %)
3 36 (60.0 %)
Histotype
Serous 40 (66.7 %)
Non-serous 20 (33.3 %)
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Because Twist was identified as a potential target of
miR-548c (Fig. 3b), we speculated that Twist serves as a
direct target of miR-548c. Our western blot analysis sug-
gested that the introduction of anti-548c led to an
increase in Twist protein level in RL95-2 cells, while
pre-548c resulted in the opposite effects in HEC-1 and
SKOV-3 cells (Fig. 3c). To test whether miR-548c re-
pression is mediated through the predicted binding site,
the reporter plasmid containing putative miR-548c re-
sponsive site was transfected with anti-548c or anti-ctr
into RL95-2 cells. The downregulation of miR-548c
enhanced Twist 3’-UTR luciferase reporter activity com-
pared with the negative control (Fig. 3d, left), suggesting
that miR-548c suppresses translation of Twist. To verify
that miR-548c directly represses Twist on its 3’-UTR, we




















































































































































Fig. 2 MiR-548c inhibits proliferation, migration and invasion of EC and OC cells. a Relative expression of miR-548c in two EC cell lines (RL95-2
and HEC-1) and OC cell lines (OVCAR3 and SKOV-3 was determined by qPCRs. Data is presented as the fold-change in expression compared with
RL95-2. b qPCR analysis of miR-548c expression in RL95-2 and OVCAR3 cells transfected with anti-miR-548c inhibitor (anti-548c) or control inhibitor
(anti-ctr). c miR-548c levels were measured by qPCRs in HEC-1 or SKOV-3 cells after overexpression of pre-miR-548c mimic (pre-548c) or control
mimic (pre-ctr). Cell proliferation assay (d), cell apoptosis assay (e), transwell migration (f) and matrigel invasion (g) assays were performed in indicated
cells after knockdown or overexpression of miR-548c, respectively. h Representative images from cell migration and invasion assays performed in SKOV-3
cells. **P< 0.01
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reporter into HEC-1 and SKOV-3 cells. The ectopic
expression of pre-548c caused a repression on luciferase
activity as compared with pre-ctr (Fig. 3d, middle and
right). To further evaluate the interaction between miR-
548c and Twist 3’-UTR, we generated Twist 3’-UTR
mutated for miR-548c binding site and performed the
luciferase assays upon either miR-548c overexpression
or knockdown. Mutant 3’-UTR reporter activity was
resistant to the addition of anti-548c or pre-548c
(Fig. 3d), confirming that Twist is a direct target of miR-
548c, and binding of miR-548c to the 3’-UTR of Twist
mRNA is sufficient to reduce Twist protein levels.
Twist binds the E-cadherin promoter and represses
E-cadherin transcription, whereas directly activating
N-cadherin expression [28, 29]. In addition, the EMT
induction has been linked to the emergence of a
Fig. 3 Twist is a direct target of miR-548c in EC and OC cells. a In silico prediction and molecular pathway enrichment analysis indicate that miR-
548c-regulated genes are preferentially involved in pathway associated with tumor growth and metastasis. The top-20 ranking KEGG pathways
were listed. b The putative conserved miR-548c-binding site in the Twist 3’-UTR. Mutation was generated in the binding site. c Western blotting
analysis of Twist expression in RL95-2, HEC-1 or SKOV-3 cells after knockdown or overexpression of miR-548c. d Indicated cells were transfected
with reporter constructs containing either wild-type (WT) Twist, or Twist 3’-UTR with mutation (Mut), along with miR-548c mimic, anti-miR-548c
inhibitor or negative controls, respectively. Relative luciferase activity was assayed. e qPCR analysis of EMT, invasion and stemness-related genes in
RL95-2 upon miR-548c knockdown, or in HEC-1 or SKOV-3 cells after overexpression of miR-548c. **P < 0.01
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cancer stem cell (CSC)-like phenotype [30]. Consist-
ent with this notion, sorted CD133+ EC cells have
been shown to demonstrate greater tumor initiating
capacity than CD133− cells [31], and CSC-like cells
obtained from SKOV-3 cells express higher levels of
CD133 [32]. Matrix metalloproteinase 9 (MMP-9) is a
downstream target of Twist in tumor cells [33]. We
test whether miR-548c regulates these genes in cancer
cells used in this study. By using qPCR, we found a
significant decrease in the expression of E-cadherin
and an increased expression in N-cadherin, CD133
and MMP-9 levels in anti-548c-transfected RL95-2
cells (Fig. 3e). In contrast, miR-548c overexpression
in HEC-1 and SKOV-3 cells significantly induced E-
cadherin levels, but inhibited the expression of N-cad-
herin, CD133 and MMP-9 (Fig. 3e). Furthermore, we
used qPCR to examine the mRNA expression of
Twist in EC and OC tissues. As expected, Twist levels
was markedly elevated in EC samples when compared
to adjacent normal tissues (Fig. 1c). We also observed
significantly increased Twist expression in OCs rela-
tive to normal ovarian tissues, and found higher levels
of Twist in serous, advanced, high-grade ovarian can-
cers (Fig. 1d). Altogether, these data are consistent
with our hypothesis that increased Twist expression
in EC and OC is a functional consequence of miR-
548c repression (at least in part).
Twist mediates miR-548c-reduced cancer cell migration
and invasion
To further study whether miR-548c can attenuate onco-
genic phenotypes in EC and OC cells through downreg-
ulation of Twist, we performed cell proliferation,
migration and invasion assays using EC or OC cells
transduced with anti-548c or pre-548c, along with either
Twist siRNA or Twist cDNA expression plasmid with-
out 3’-UTR sequence, which renders the escape from
miR-548c regulation. Anti-548c-induced RL95-2 cell
proliferation, migration and invasion were significantly
abrogated by Twist siRNA (Fig. 4a, c and e). On the
other hand, overexpression of Twist cDNA largely res-
cued pre-548c-suppressed proliferation, migration and
invasion in HEC-1 cells (Fig. 4b, d and f, left). Although
expression of Twist cDNA restored SKOV-3 cell migra-
tion and invasion that were reduced by pre-548c (Fig. 4d
and f, right), cell proliferative phenotype was not signifi-
cantly restored by Twist overexpression in SKOV-3 cells
(Fig. 4b, right), consistent with a previous report show-
ing that Twist confers migratory and invasive potential,

















































































































Fig. 4 Twist mediates miR-548c-reduced cancer cell proliferation, migration and invasion. RL95-2, HEC-1 and SKOV-3 cells were transfected with anti-548c,
pre-548c, Twist siRNA or Twist cDNA vector lacking 3’-UTR as indicated, and were assayed for cell proliferation (a, b), migration (c, d) and invasion (e, f) (top).
Western blot analysis of Twist protein levels (bottom). **P< 0.01
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Collectively, these data support the mechanistic roles for
miR-548c in impairing migration and invasion of EC
and OC cells by targeting Twist.
Discussion
Targeting of metastasis-related miRNAs in human tu-
mors may offer potential therapeutic strategies for these
diseases [34, 35]. Recent findings have identified miR-
548c family members as universe miRNA, and illustrated
the possibility that these miRNAs exert broad effects on
many features of tumor cells through a broad range of
targets and pathways [17]. Although one such miRNA,
miR-548c, has been shown to inhibit cancer cell growth
[19], its cellular functions, underlying mechanisms and
clinical significance have not been comprehensively
studied in gynecological cancers. Here, we found that
miR-548c was under-expressed in both EC and OC sam-
ples, compared to their non-tumor counterparts. At the
molecular level, miR-548c represses migration and inva-
sion of EC and OC cells partially by targeting Twist. We
demonstrate that miR-548c expression was inversely cor-
related with Twist level in EC and OC tissues, and re-
duced miR-548c expression was associated with poor
prognosis in EC patients. These findings reveal for the
first time that in EC and OC cells, miR-548c is a tumor-
suppressive miRNA that inhibits multiple malignant
features of the metastatic cascade.
Twist has been known as a novel oncogene overex-
pressed in diverse tumors [36], and activation of Twist in-
hibits apoptosis and promotes the induction of EMT,
cancer stemness, proliferation, angiogenesis and vasculo-
genic mimicry in human tumor cells, all of which contrib-
utes to metastasis [37, 38]. Several upstream regulators
and downstream effector of Twist have been reported
[37], however our knowledge of the detailed molecular
mechanisms involved in Twist overexpression, especially
the epigenetic regulation of Twist expression, is still in-
complete. Here, we reported a previously unidentified
mechanism whereby loss of miR-548c expression is par-
tially responsible for increased Twist levels in EC and OC,
two of the most common gynecologic cancers.
Twist has been shown to upregulate the expression of
some miRNAs, such as miR-10b [39] and miR-424 [40].
Twist promotes the expression of miR-10b by directly
binding to the promoter of miR-10b, which initiates
tumor invasion and metastasis in breast cancer [39].
Furthermore, miR-424, another miRNA that can be in-
duced by Twist, drives EMT-like phenotypes in breast
cancers [40]. The impact of Twist on miR-548c expres-
sion in EC and OC cells warrants further investigation.
MiR-548c was reported to be an independent prognostic
factor for breast cancer. Patients with a good prognosis
presented higher intratumoral expression of miR-548c
[41]. Consistently, our meta-analysis suggested that high
expression of miR-548c in EC and OC appears to correlate
with better survival in patients with EC and OC, implying
that miR-548c may be a new promising prognostic factor
in these cancers. Since miR-548c directly regulates Twist
in EC and OC cells, this miRNA might also represent an
attractive target for the treatment of Twist-overexpressing
tumors.
Conclusions
Our findings provide a novel mechanism by which the
repression of miR-548c increases Twist levels to stimu-
late cancer cell migration and invasion of both EC and
OC cells. Our results indicate that miR-548c is a poten-
tial therapeutic target in EC and OC.
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